Curis, Inc. · NASDAQ:CRIS
Curis — Technical Presentation (2021)
9 slides from Curis's technical presentation, 2021
Slide 1: Pharmacological inhibition of IRAK4 with CA-4948 in marginal zone lymphoma models
Pharmacological inhibition of IRAK4 with CA-4948 is beneficial in marginal zone lymphoma models with secondary resistance to PI3K and BTK inhibitors Francesca Guidetti 1, Alberto J. Arribas 1,2, Filippo Spriano 1, Laura Barnabei 1, Reinhard von Roemeling 3, Elizabeth Martinez 3, Emanuele Zucca 1,4,
Slide 2: Financial relationships to disclose
Financial relationships to disclose Speaker Name: Francesca Guidetti Francesco Bertoni received institutional funds from Curis, Inc, Lexington, MA, USA Reinhard von Roemeling , Elizabeth Martinez are employees of Curis Inc, Lexington, MA, USA
Slide 3: Targeting pathogenic mechanisms in marginal zone lymphoma
Targeting pathogenic mechanisms in marginal zone lymphoma BCR signaling inhibitors Ibrutinib (BTK inhibitor) CA-4948 first-in-class inhibitor of IRAK4 Copanlisib (PI3K alpha-delta inhibitor) Idelalisib (PI3K-delta inhibitor) Modified from: J. K. Lue, O. A. O’Connor, F. Bertoni. Annals of Lymphoma (2
Slide 4: Pharmacological screening of IRAK4 inhibition with CA-4948
Pharmacological screening of IRAK4 inhibition with CA-4948 Ibrutinib VL51 (MZL), Ibrutinib-resistant Copanlisib CA-4948 VL51 (MZL), Copanlisib-resistant + (72 hours treatment) Idelalisib Karpas1718, VL51 (MZL), Idelalisib- resistant Cell viability tested by MTT assay as previously described (Tarante
Slide 5: Pharmacological screening of IRAK4 inhibition with CA-4948
Pharmacological screening of IRAK4 inhibition with CA-4948 CA-4948 treatment as single agent CA-4948 72h treatment in combination to PI3K/BTK inhibitors in resistant and parental in vitro models in resistant and parental in vitro models Copanlisib Idelalisib Ibrutinib (Guidetti et al, on-going)
Slide 6: The combination of CA4948 and ibrutinib is synergistic in ibrutinib-resistant cells
The combination of CA4948 and ibrutinib is synergistic in ibrutinib-resistant cells CA-4948 in combination with ibrutinib in VL51 parental and ibrutinib resistant models (Guidetti et al, on-going)
Slide 7: The combination of CA4948 and idelalisib is superior to single agents
The combination of CA4948 and idelalisib is superior to single agents in resistant and parental models CA-4948 in combination with idelalisib in VL51 and K1718 parental and idelalisib resistant models (Guidetti et al, on-going)
Slide 8: The combination of CA4948 and copanlisib is beneficial in resistant and parental models
The combination of CA4948 and copanlisib is beneficial in copanlisib-resistant and parental models CA-4948 in combination with copanlisib in VL51 parental and copanlisib resistant models (Guidetti et al, on-going)
Slide 9: Addition of CA4948 increases sensitivity to PI3K or BTK inhibitors
Addition of CA4948 increases sensitivity to PI3K or BTK inhibitors (Guidetti et al, on-going)